Real-world outcome data from patients with non-metastatic prostate cancer treated with primary androgen deprivation therapy

Abstract

Purpose: Primary androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone agonists/antagonists and non-steroidal anti-androgens is used in patients with non-metastatic prostate cancer who are unable to undergo radical treatment. Due to an aging and increasingly comorbid population, the prevalence of these patients is increasing. Therefore, we aimed to assess the long-term survival outcomes of patients treated at our centre.